This monograph is the first in a series from the Endocrine Society. Each monograph will include a number of articles recently published in Endocrine Reviews and focus on a particular topic. These artiles have all been peer revied and, as a clever addition, the authors have prepared addenda that update the articles which appeared originally between 1990 and 1992.
Of the ten chapters in Endorn Aspects of Cancer, the first six address issues dealing with hormones and breast (Lamberts et al.) and the cellular sources and biological functions of cytokines (Kurzrock et al.) .
Overall these ten chapters are high-quality critical, in-depth state-of-the-art reviews. The book is well produced and reasonably priced. My only quibble is with the content mix. The six chapters on breast cancer fit together beaufifully, but the remainder are more like four isolated additions. Clinicians and probably scientists interested in dopamine agonists and pituitary tumours are unlikely to be equally interest in breast or ovarian cncer and vice versa. As the treatment of children with cancer has improved, concern about possible late effects has also increased. Over half the children diagnosed with cancer will now survive more than 5 years, and one important potential cause of late excess mortality among these survivors is treatment-related cardiac damage. Subsequent chapters in the book discuss the pathology of radiation and anthracyclne-induced heart disease. Fajardo concludes that radiation should not be viewed an an independent cause of coronary artery disease, but as a co-factor with the agents already known to be associated with this disease, sine there is no difference in the pathology of arterial lesions caused by radiation and those produced by spontaneous atherosclerosis. Adriamycin does aggravate radiation injury through a final common end point of diffuse myocrdial fibrosis, but, whereas for radiation this fibrosis is produced by endotheial damage, for adriamycin there is direct toxic effect on myocytes which are then replaced by fibrotic tissue. The changes produced by adriamycin have been elucidated by endomyocardial biopsy, which has made it possible to detect early changes. After papers disussing the pathology and pathophysiology of anthracycline cardiac toxicity, the epidemiology of radiation-related heart disease based on data from Stanford University is discussed by Hancock and Donaldson, who have identified 12 heart disease deaths in their group of 635 children and adolescents treated.
The second part of the book is devoted to papers on ways of monitoring anthracycie therapy in the short and long term, with regard to the factors summarised by Bricker in his introduction. Ewer and Benjamin discuss possible ways of preventing cardiac dam by modifying the way the drug is given, and Berg and collagues discuss the use of cardiac protectant agents such as ICRF 187 in modifying the toxicity of adriamycin.
The final chapter addresses the role of genetic counselling and the ways in which progress i genetics may make it possible to identify individuals with significntly icreased risks of developing late complications of cancer treatment.
The papers are clearly and coherently written and provide an excellent overview of the subject of cardiac toxicity. It is an important summary of the current situation both for clinicians caring for children receiving cardiotoxic therapy and for those concered with developing new strategies to minimise problems in the future.
A. Barrett 1e a & Ly_phoma Reviews 2 Edited by A. Polliack, Chur, Switzerland: Harwood Academic Publishers, 1993, 297pp. £48.00.
This book represents the second in a series of books, the contents of which have been derived from review articles published in the journal Leukemia and Lymphoma. This relatively new journal has rapidly become established as an important vehicle for publications in haematological oncology. The authors have gathered reviews from volumes 5, 6
